Advertisement

Reactions Weekly

, Volume 1779, Issue 1, pp 137–137 | Cite as

Immunotherapies

Active Mycobacterium tuberculosis: 2 case reports
Case report
  • 71 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series, a 76-year-old woman (Case 1) and an 85-year-old man (Case 2) were described, who developed active Mycobacterium tuberculosis (MTB) while receiving immunotherapy with ipilimumab/nivolumab, nivolumab, atezolizumab or cobimetinib [routes not stated] for melanoma.

Case 1: A 76-year-old woman, who had advanced melanoma, was enrolled in a clinical trial (Study no: NCT03068455). She was randomised to receive monotherapy with nivolumab 240mg every 2 weeks against the combination of ipilimumab/nivolumab 1 mg/kg every 3 weeks. Her medical history was significant for smoking, dyslipidemia, hypertension, coronary artery disease and osteopenia. In January 2018, following 8 doses of immunotherapy, she presented with grade 2 diarrhoea and started oral methylprednisolone 16mg...

Reference

  1. Anastasopoulou A, et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: Current evidence and clinical practice recommendations. Journal for ImmunoTherapy of Cancer 7: 239, No. 1, 4 Sep 2019. Available from: URL: http://doi.org/10.1186/s40425-019-0717-7 - Greece

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations